Moderna And Merck Say Their mRNA Cancer Vaccine Cut Death, Recurrence By 42%

TL;DR

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

Moderna and Merck say their personalized mRNA vaccine, intismeran, combined with Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda and placebo in a Phase 3 trial. At two years, 82% of the vaccine group and 70% of the comparison group were alive without recurrence; longer follow-up and further details remain relevant.

Moderna and Merck said their personalized mRNA vaccine, intismeran, combined with Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda plus placebo in a Phase 3 trial. The companies reported that, after two years, 82% of patients receiving the vaccine combination were alive without recurrence, versus 70% in the comparison group.

The trial tested intismeran, also known as mRNA-4157, alongside Merck’s immunotherapy Keytruda in people with melanoma whose tumors had been surgically removed. The comparison group received Keytruda and a placebo. The reported 42% figure describes the relative reduction in risk of recurrence or death between the groups; it is not the percentage-point difference in the share of patients alive without recurrence.

The companies also reported a 38% reduction in the risk of distant metastasis or death for the vaccine combination compared with Keytruda and placebo. At the reported assessment, 88.5% of the combination group were alive without distant metastasis, compared with 80% of the comparison group. Distant metastasis means cancer has spread to a part of the body away from where it began.

The results were described in a company announcement and reported by Ars Technica. The measures used were recurrence-free survival (RFS), the time patients remain without a return of cancer, and distant metastasis-free survival (DMFS), the time they remain without distant spread. The available source material does not provide the full trial publication or detailed safety data, so the reported figures should be read as company-reported results.

A New Option After Melanoma Surgery

For patients whose melanoma has been removed, treatment after surgery aims to lower the chance that the cancer returns or spreads. The reported difference in two-year recurrence-free outcomes suggests that adding a personalized vaccine to Keytruda may improve on Keytruda alone in this trial population. The result is relevant because it comes from a Phase 3 study, a late-stage test intended to evaluate a treatment in a larger group before possible regulatory decisions.

The results do not mean that every patient will benefit, nor do they establish that the vaccine combination is appropriate for all melanoma cases. The reported 42% reduction is a comparison of risk, while the observed two-year shares alive without recurrence differed by 12 percentage points. Patients and clinicians would need fuller information on benefits, risks, eligibility and treatment logistics to judge what the findings mean for individual care.

How the Personalized Vaccine Is Made

Intismeran is designed around mutations found in an individual patient’s tumor. According to the source report, researchers compare genetic sequences from cancer cells with those from healthy cells, then select cancer-specific mutations to include in a synthetic mRNA vaccine. The vaccine can encode up to 34 tumor mutations, with the aim of prompting an immune response directed at the patient’s cancer.

The Phase 3 results follow earlier findings from a five-year Phase 2 trial. That study reported a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk. The newer reported figures—42% and 38%, respectively—are smaller, and the trials’ results should not be treated as directly interchangeable without full study details. Merck Research Laboratories president Dean Li called the Phase 3 findings a first for the study setting, saying the trial showed improvement over standard-of-care Keytruda in resected melanoma.

“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.””

— Dean Li, president of Merck Research Laboratories

Trial Details Still Await Review

The source material does not include a full peer-reviewed paper, the number of participants, confidence intervals, statistical significance details, or a complete account of adverse events. It is also not clear from the provided report how the reported two-year assessment was timed for each participant or how the results may change with longer follow-up. Those details are needed to assess the precision and durability of the findings.

The results concern a specific group: people with surgically removed melanoma receiving the tested treatment regimen. They do not establish effectiveness for other cancers, patients with unresected disease, or use of the vaccine without Keytruda. The companies’ announcement also does not by itself establish regulatory approval or routine availability.

Longer Follow-Up and Review Ahead

The next questions are whether the results appear in a full scientific publication, how safety and subgroup outcomes compare, and whether follow-up confirms that the benefit persists beyond two years. Additional regulatory and clinical review would be needed before any change in treatment guidance or access. The available source does not specify a publication date, regulatory filing timetable, or when the companies expect to provide further data.

Key Questions

What did the Phase 3 trial report?

Moderna and Merck reported that intismeran plus Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda and placebo. At two years, 82% of the combination group and 70% of the comparison group were alive without recurrence.

Does a 42% reduction mean 42% more patients avoided recurrence?

No. The 42% figure is a reported relative reduction in risk. The reported shares alive without recurrence were 82% and 70%, a difference of 12 percentage points at the two-year assessment.

What is intismeran?

Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed using mutations identified in a patient’s tumor. In the trial, it was given with Keytruda after melanoma surgery.

Is the vaccine approved or available as standard treatment?

The source material reports trial findings and does not establish regulatory approval or routine availability. The companies’ announcement alone does not change treatment guidance.

What information is still missing?

The supplied report does not include the full trial paper, participant count, detailed statistical measures, or complete safety results. Longer follow-up will also help clarify how durable the reported benefit is.

Source: hn